PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy.
作者信息
Gualdi G, Moro R, Regina V, Caravello S, Monari P, Calzavara-Pinton P G
机构信息
Department of Dermatology, ASST Spedali Civili di Brescia, Brescia, Italy.
出版信息
Br J Dermatol. 2019 Aug;181(2):406-407. doi: 10.1111/bjd.17754. Epub 2019 May 6.
PMID:30737996
Abstract
摘要
相似文献
1
PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy.PRI模式吉莫单抗：使用PRISM测试评估接受Hedgehog通路抑制剂治疗的局部晚期基底细胞癌患者的健康相关生活质量。
Br J Dermatol. 2019 Aug;181(2):406-407. doi: 10.1111/bjd.17754. Epub 2019 May 6.
2
Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience.在使用刺猬信号通路抑制剂维莫德吉对局部晚期基底细胞癌进行常规治疗期间，通过降低剂量来管理不良反应：一项单中心经验。
J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e144-e145. doi: 10.1111/jdv.15367. Epub 2018 Dec 17.
3
Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.维莫德吉在晚期基底细胞癌中的疗效：基于模型的评估，8周剂量中断后疗效得以维持
J Invest Dermatol. 2021 Apr;141(4):930-933. doi: 10.1016/j.jid.2020.07.036. Epub 2020 Sep 22.
4
Four-year experience with vismodegib hedgehog inhibitor therapy.维莫德吉（vismodegib）刺猬因子抑制剂治疗的四年经验
J Am Acad Dermatol. 2016 Jun;74(6):1264-5. doi: 10.1016/j.jaad.2015.12.035.
5
Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.在基底细胞癌治疗中处理与维莫德吉相关的不良事件。
Future Oncol. 2017 Jan;13(2):175-184. doi: 10.2217/fon-2016-0296. Epub 2016 Sep 19.
6
Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma.基底细胞癌刺猬通路抑制剂治疗不良反应的实际管理
J Am Acad Dermatol. 2017 Apr;76(4):767-768. doi: 10.1016/j.jaad.2016.04.063.
7
Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing.维莫德吉延长隔日给药治疗基底细胞癌的疗效
Dermatol Surg. 2020 Aug;46(8):1109-1112. doi: 10.1097/DSS.0000000000001985.
8
Report of cutaneous side effects of vismodegib treatment.维莫德吉治疗皮肤副作用的报告。
Clin Exp Ophthalmol. 2020 Jan;48(1):123-125. doi: 10.1111/ceo.13651. Epub 2019 Oct 20.
9
Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.在一项开放性、前瞻性病例系列临床试验中，评估了短疗程（12-24 周）口服维莫德吉在各种组织学亚型（浸润性、结节性和浅表性）高危或局部晚期基底细胞癌中的疗效、肿瘤缓解率和安全性。
J Am Acad Dermatol. 2020 Apr;82(4):946-954. doi: 10.1016/j.jaad.2019.12.002. Epub 2019 Dec 10.
10
Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience.维莫德吉治疗基底细胞癌患者的疗效与安全性：意大利某中心的经验
Dermatol Ther. 2019 Jul;32(4):e12971. doi: 10.1111/dth.12971. Epub 2019 Jun 12.
引用本文的文献
1
A systematic review of patient-reported outcome measures for advanced skin cancer patients.晚期皮肤癌患者报告结局测量的系统评价。
Arch Dermatol Res. 2023 Aug;315(6):1473-1480. doi: 10.1007/s00403-022-02479-0. Epub 2022 Dec 5.
2
Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI).维莫德吉停药后的长期疗效以及使用皮肤病生活质量指数（DLQI）评估患者的健康相关生活质量。
Dermatol Ther (Heidelb). 2019 Dec;9(4):719-724. doi: 10.1007/s13555-019-00323-4. Epub 2019 Sep 10.
3
Real-Life Effectiveness of Vismodegib in Patients with Metastatic and Advanced Basal Cell Carcinoma: Characterization of Adverse Events and Assessment of Health-Related Quality of Life using the Dermatology Life Quality Index (DLQI) Test.维莫德吉在转移性和晚期基底细胞癌患者中的实际疗效：不良事件特征及使用皮肤病生活质量指数（DLQI）测试评估健康相关生活质量
Dermatol Ther (Heidelb). 2019 Sep;9(3):505-510. doi: 10.1007/s13555-019-0303-4. Epub 2019 Jun 4.
Zotero 插件